Pancreatic Duodenal Homeobox Factor-1 (PDX-1) and Neurogenin-3 (NGN-3) in Gestational Diabetes
NCT ID: NCT03964987
Last Updated: 2019-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2018-01-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Material and methods: This was a prospective, clinical and cross-sectional study, conforming two groups of pregnant women: a) patients with a healthy gestation and b) patients with GDM. Besides anthropometry and routine laboratorial test, real-time polymerase chain reaction (Real-Time PCR), was used to quantify the expression of PDX-1 and NGN-3.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Maternal Serum Pentraxin 3 in Early Pregnancy to Predict Gestational Diabetes Mellitus
NCT03563638
Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development
NCT01623934
Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia
NCT01649167
Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor
NCT05742997
Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus
NCT03570632
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
From all patients the next information was captured in an excell sheet: weight, height, Body Mass Index, blood pressure, albumin, creatinine, electrolytes, glucose, total cholesterol, triglycerides, transaminases and relative expression of PDX-1 and NGN-3.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Women with normoevolutionary gestation.
No interventions assigned to this group
Problem group
Patients with GDM.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Autonoma del Estado de Mexico
OTHER
Materno-Perinatal Hospital of the State of Mexico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hugo Mendieta Zeron
Chief of the Research Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugo Mendieta Zerón, PhD.
Role: PRINCIPAL_INVESTIGATOR
Maternal-Perinatal Hospital "Mónica Pretelini Sáenz"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Materno-Perinatal Hospital "Mónica Pretelini"
Toluca, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sandikci M, Karagenc L, Yildiz M. Changes on the Pancreas in Experimental Diabetes and the Effect of Lycopene on These Changes: Pdx-1, Ngn-3, and Nestin Expressions. Anat Rec (Hoboken). 2017 Dec;300(12):2200-2207. doi: 10.1002/ar.23687. Epub 2017 Sep 26.
Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development. 2002 May;129(10):2447-57. doi: 10.1242/dev.129.10.2447.
Wang L, Fan H, Zhou L, Wu Y, Lu H, Luo J. Altered expression of PGC-1alpha and PDX1 and their methylation status are associated with fetal glucose metabolism in gestational diabetes mellitus. Biochem Biophys Res Commun. 2018 Jun 18;501(1):300-306. doi: 10.1016/j.bbrc.2018.05.010. Epub 2018 May 7.
Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The Pathophysiology of Gestational Diabetes Mellitus. Int J Mol Sci. 2018 Oct 26;19(11):3342. doi: 10.3390/ijms19113342.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-09-481
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.